Eko ensures all patients have access to early cardiac and pulmonary disease detection and high-quality care that improves and extends their lives.
Eko is advancing how healthcare professionals detect and monitor heart and lung disease with its suite of digital tools, patient and provider software, and AI-powered analysis. Its FDA-cleared platform is used by healthcare professionals worldwide, allowing them to detect earlier and with higher accuracy, diagnose with more confidence, manage treatment effectively, and ultimately give their patients the best care possible. Eko has over $125 million in funding from Highland Capital Partners, Questa Capital, Artis Ventures, DigiTx Partners, NTTVC, Morningside Technology Ventures Limited, Mayo Clinic, Sutter Health, and others.
ACC.23 Learning Pathways? (select all that apply) Heart Failure and Cardiomyopathies, Interventional and Structural Cardiology, Valvular Heart Disease
First time Exhibitor? No